Boosting Drug Discovery for Parkinson’s: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles

Boosting Drug Discovery for Parkinson’s: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles

The current pharmacological treatments for Parkinson’s disease only offer symptomatic relief to the patients and are based on the administration of levodopa and catechol-O-methyltransferase or monoamine oxidase-B inhibitors (IMAO-B). Since the majority of drug candidates fail in pre- and c...

Full description

Bibliographic Details
Main Authors: Miguel Pinto, Carlos Fernandes, Eva Martins, Renata Silva, Sofia Benfeito, Fernando Cagide, Ricardo F. Mendes, Filipe A. Almeida Paz, Jorge Garrido, Fernando Remião, Fernanda Borges
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Pharmaceutics
Subjects:
Parkinson disease
chromone
monoamine oxidase B inhibitor
PEGylated nanoparticles
intestinal and brain permeability
Online Access:https://www.mdpi.com/1999-4923/11/7/331

Internet

https://www.mdpi.com/1999-4923/11/7/331

Similar Items